<?xml version="1.0" encoding="UTF-8"?>
<urlset xmlns="http://www.sitemaps.org/schemas/sitemap/0.9" xmlns:news="http://www.google.com/schemas/sitemap-news/0.9" xmlns:ns="http://www.google.com/schemas/sitemap-pagemap/1.0" xmlns:image="http://www.google.com/schemas/sitemap-image/1.1">
  <url>
    <loc>https://www.businesswire.com/news/home/20260110393219/en/BBNX-Investors-Have-Opportunity-to-Join-Beta-Bionics-Inc.-Fraud-Investigation-with-the-Schall-Law-Firm</loc>
    <lastmod>2026-01-10T22:23:00.000Z</lastmod>
    <changefreq>weekly</changefreq>
    <priority>0.5</priority>
    <news:news>
      <news:publication>
        <news:name>Business Wire</news:name>
        <news:language>en</news:language>
      </news:publication>
      <news:genres>PressRelease</news:genres>
      <news:publication_date>2026-01-10T22:23:00.000Z</news:publication_date>
      <news:title>BBNX Investors Have Opportunity to Join Beta Bionics, Inc. Fraud Investigation with the Schall Law Firm</news:title>
      <news:stock_tickers>BBNX</news:stock_tickers>
    </news:news>
    <ns:PageMap>
      <ns:DataObject type="thumbnail">
        <ns:Attribute name="name" value=""/>
        <ns:Attribute name="src" value="https://mms.businesswire.com/media/20260110393219/en/827144/21/Schall-Firm-Logo-640x360.jpg"/>
        <ns:Attribute name="width" value="150"/>
        <ns:Attribute name="height" value="150"/>
      </ns:DataObject>
    </ns:PageMap>
    <image:image>
      <image:loc>https://mms.businesswire.com/media/20260110393219/en/827144/21/Schall-Firm-Logo-640x360.jpg</image:loc>
    </image:image>
  </url>
  <url>
    <loc>https://www.businesswire.com/news/home/20260110381133/en/ARDT-Investors-Have-Opportunity-to-Lead-Ardent-Health-Inc.-Securities-Fraud-Lawsuit-with-the-Schall-Law-Firm</loc>
    <lastmod>2026-01-10T21:23:00.000Z</lastmod>
    <changefreq>weekly</changefreq>
    <priority>0.5</priority>
    <news:news>
      <news:publication>
        <news:name>Business Wire</news:name>
        <news:language>en</news:language>
      </news:publication>
      <news:genres>PressRelease</news:genres>
      <news:publication_date>2026-01-10T21:23:00.000Z</news:publication_date>
      <news:title>ARDT Investors Have Opportunity to Lead Ardent Health, Inc. Securities Fraud Lawsuit with the Schall Law Firm</news:title>
      <news:stock_tickers>ARDT</news:stock_tickers>
    </news:news>
    <ns:PageMap>
      <ns:DataObject type="thumbnail">
        <ns:Attribute name="name" value=""/>
        <ns:Attribute name="src" value="https://mms.businesswire.com/media/20260110381133/en/827144/21/Schall-Firm-Logo-640x360.jpg"/>
        <ns:Attribute name="width" value="150"/>
        <ns:Attribute name="height" value="150"/>
      </ns:DataObject>
    </ns:PageMap>
    <image:image>
      <image:loc>https://mms.businesswire.com/media/20260110381133/en/827144/21/Schall-Firm-Logo-640x360.jpg</image:loc>
    </image:image>
  </url>
  <url>
    <loc>https://www.businesswire.com/news/home/20260109805641/es</loc>
    <lastmod>2026-01-10T18:55:00.000Z</lastmod>
    <changefreq>weekly</changefreq>
    <priority>0.5</priority>
    <news:news>
      <news:publication>
        <news:name>Business Wire</news:name>
        <news:language>es</news:language>
      </news:publication>
      <news:genres>PressRelease</news:genres>
      <news:publication_date>2026-01-10T18:55:00.000Z</news:publication_date>
      <news:title>Blockstream Capital Partners anuncia la adquisición estratégica del equipo de trading de derivados de Numeus Group, lo que habilita su alianza estratégica con Komainu</news:title>
    </news:news>
    <ns:PageMap>
      <ns:DataObject type="thumbnail">
        <ns:Attribute name="name" value=""/>
        <ns:Attribute name="src" value="https://mms.businesswire.com/media/20260109805641/es/2687266/21/Logo_Colour.jpg"/>
        <ns:Attribute name="width" value="150"/>
        <ns:Attribute name="height" value="150"/>
      </ns:DataObject>
    </ns:PageMap>
    <image:image>
      <image:loc>https://mms.businesswire.com/media/20260109805641/es/2687266/21/Logo_Colour.jpg</image:loc>
    </image:image>
  </url>
  <url>
    <loc>https://www.businesswire.com/news/home/20260110058494/en/Kinaset-Therapeutics-Announces-%24103-Million-Oversubscribed-Series-B-Financing-to-Advance-Novel-Inhaled-Therapeutic-Candidate-for-Respiratory-Diseases</loc>
    <lastmod>2026-01-10T16:35:00.000Z</lastmod>
    <changefreq>weekly</changefreq>
    <priority>0.5</priority>
    <news:news>
      <news:publication>
        <news:name>Business Wire</news:name>
        <news:language>en</news:language>
      </news:publication>
      <news:genres>PressRelease</news:genres>
      <news:publication_date>2026-01-10T16:35:00.000Z</news:publication_date>
      <news:title>Kinaset Therapeutics Announces $103 Million Oversubscribed Series B Financing to Advance Novel, Inhaled Therapeutic Candidate for Respiratory Diseases</news:title>
    </news:news>
    <ns:PageMap>
      <ns:DataObject type="thumbnail">
        <ns:Attribute name="name" value=""/>
        <ns:Attribute name="src" value="https://mms.businesswire.com/media/20260110058494/en/2687927/21/kinaset_tx_logo.jpg"/>
        <ns:Attribute name="width" value="150"/>
        <ns:Attribute name="height" value="150"/>
      </ns:DataObject>
    </ns:PageMap>
    <image:image>
      <image:loc>https://mms.businesswire.com/media/20260110058494/en/2687927/21/kinaset_tx_logo.jpg</image:loc>
    </image:image>
  </url>
  <url>
    <loc>https://www.businesswire.com/news/home/20260108419714/en/Pfizers-BRAFTOVI-Regimen-with-Additional-Chemotherapy-Backbone-Increased-Response-Rates-for-Certain-Patients-with-Metastatic-Colorectal-Cancer</loc>
    <lastmod>2026-01-10T15:00:00.000Z</lastmod>
    <changefreq>weekly</changefreq>
    <priority>0.5</priority>
    <news:news>
      <news:publication>
        <news:name>Business Wire</news:name>
        <news:language>en</news:language>
      </news:publication>
      <news:genres>PressRelease</news:genres>
      <news:publication_date>2026-01-10T15:00:00.000Z</news:publication_date>
      <news:title>Pfizer’s BRAFTOVI® Regimen with Additional Chemotherapy Backbone Increased Response Rates for Certain Patients with Metastatic Colorectal Cancer</news:title>
      <news:stock_tickers>PFE</news:stock_tickers>
    </news:news>
    <ns:PageMap>
      <ns:DataObject type="thumbnail">
        <ns:Attribute name="name" value=""/>
        <ns:Attribute name="src" value="https://mms.businesswire.com/media/20260108419714/en/1045874/21/Pfizer_Logo_Color_RGB_APPROVED.jpg"/>
        <ns:Attribute name="width" value="150"/>
        <ns:Attribute name="height" value="150"/>
      </ns:DataObject>
    </ns:PageMap>
    <image:image>
      <image:loc>https://mms.businesswire.com/media/20260108419714/en/1045874/21/Pfizer_Logo_Color_RGB_APPROVED.jpg</image:loc>
    </image:image>
  </url>
  <url>
    <loc>https://www.businesswire.com/news/home/20260109800447/fr</loc>
    <lastmod>2026-01-10T14:14:00.000Z</lastmod>
    <changefreq>weekly</changefreq>
    <priority>0.5</priority>
    <news:news>
      <news:publication>
        <news:name>Business Wire</news:name>
        <news:language>fr</news:language>
      </news:publication>
      <news:genres>PressRelease</news:genres>
      <news:publication_date>2026-01-10T14:14:00.000Z</news:publication_date>
      <news:title>MindWalk fait avancer le programme universel de lutte contre la grippe grâce à des informations fonctionnelles pionnières</news:title>
      <news:stock_tickers>HYFT</news:stock_tickers>
    </news:news>
    <ns:PageMap>
      <ns:DataObject type="thumbnail">
        <ns:Attribute name="name" value=""/>
        <ns:Attribute name="src" value="https://mms.businesswire.com/media/20260109800447/fr/2586413/21/Mindwalk_fullcolor_RGB_LG.jpg"/>
        <ns:Attribute name="width" value="150"/>
        <ns:Attribute name="height" value="150"/>
      </ns:DataObject>
    </ns:PageMap>
    <image:image>
      <image:loc>https://mms.businesswire.com/media/20260109800447/fr/2586413/21/Mindwalk_fullcolor_RGB_LG.jpg</image:loc>
    </image:image>
  </url>
  <url>
    <loc>https://www.businesswire.com/news/home/20260109701562/en/Stride-72-Hour-Deadline-Alert-Kahn-Swick-Foti-LLC-Reminds-Investors-With-Losses-In-Excess-Of-%24100000-of-Deadline-in-Class-Action-Lawsuit-Against-Stride-Inc.---LRN</loc>
    <lastmod>2026-01-10T03:54:00.000Z</lastmod>
    <changefreq>weekly</changefreq>
    <priority>0.5</priority>
    <news:news>
      <news:publication>
        <news:name>Business Wire</news:name>
        <news:language>en</news:language>
      </news:publication>
      <news:genres>PressRelease</news:genres>
      <news:publication_date>2026-01-10T03:54:00.000Z</news:publication_date>
      <news:title>Stride 72 Hour Deadline Alert: Kahn Swick &amp; Foti, LLC Reminds Investors With Losses In Excess Of $100,000 of Deadline in Class Action Lawsuit Against Stride, Inc. - LRN</news:title>
      <news:stock_tickers>LRN</news:stock_tickers>
    </news:news>
    <ns:PageMap>
      <ns:DataObject type="thumbnail">
        <ns:Attribute name="name" value=""/>
        <ns:Attribute name="src" value="https://mms.businesswire.com/media/20260109701562/en/2664611/21/2025-PR-SEC.jpg"/>
        <ns:Attribute name="width" value="150"/>
        <ns:Attribute name="height" value="150"/>
      </ns:DataObject>
    </ns:PageMap>
    <image:image>
      <image:loc>https://mms.businesswire.com/media/20260109701562/en/2664611/21/2025-PR-SEC.jpg</image:loc>
    </image:image>
  </url>
  <url>
    <loc>https://www.businesswire.com/news/home/20260109239717/en/VRNS-INVESTOR-ALERT-Robbins-Geller-Rudman-Dowd-LLP-Announces-that-Varonis-Systems-Inc.-Investors-with-Substantial-Losses-Have-Opportunity-to-Lead-Class-Action-Lawsuit</loc>
    <lastmod>2026-01-10T03:30:00.000Z</lastmod>
    <changefreq>weekly</changefreq>
    <priority>0.5</priority>
    <news:news>
      <news:publication>
        <news:name>Business Wire</news:name>
        <news:language>en</news:language>
      </news:publication>
      <news:genres>PressRelease</news:genres>
      <news:publication_date>2026-01-10T03:30:00.000Z</news:publication_date>
      <news:title>VRNS INVESTOR ALERT: Robbins Geller Rudman &amp; Dowd LLP Announces that Varonis Systems, Inc. Investors with Substantial Losses Have Opportunity to Lead Class Action Lawsuit</news:title>
      <news:stock_tickers>VRNS</news:stock_tickers>
    </news:news>
    <ns:PageMap>
      <ns:DataObject type="thumbnail">
        <ns:Attribute name="name" value=""/>
        <ns:Attribute name="src" value="https://mms.businesswire.com/media/20260109239717/en/2313484/21/RGRD_Logo_2v2.jpg"/>
        <ns:Attribute name="width" value="150"/>
        <ns:Attribute name="height" value="150"/>
      </ns:DataObject>
    </ns:PageMap>
    <image:image>
      <image:loc>https://mms.businesswire.com/media/20260109239717/en/2313484/21/RGRD_Logo_2v2.jpg</image:loc>
    </image:image>
  </url>
  <url>
    <loc>https://www.businesswire.com/news/home/20260109704999/ja</loc>
    <lastmod>2026-01-10T03:06:00.000Z</lastmod>
    <changefreq>weekly</changefreq>
    <priority>0.5</priority>
    <news:news>
      <news:publication>
        <news:name>Business Wire</news:name>
        <news:language>ja</news:language>
      </news:publication>
      <news:genres>PressRelease</news:genres>
      <news:publication_date>2026-01-10T03:06:00.000Z</news:publication_date>
      <news:title>バイオサイトジェンとAcepodia、ファーストインクラスの二重特異性抗体およびデュアルペイロードADC（BsAD2C）開発に向けたオプション型評価枠組みを通じて提携を拡大</news:title>
      <news:stock_tickers>688796,02315</news:stock_tickers>
    </news:news>
    <ns:PageMap>
      <ns:DataObject type="thumbnail">
        <ns:Attribute name="name" value=""/>
        <ns:Attribute name="src" value="https://mms.businesswire.com/media/20260109704999/ja/2687178/21/Biocytogen-Acepodia-HI-EN.jpg"/>
        <ns:Attribute name="width" value="150"/>
        <ns:Attribute name="height" value="150"/>
      </ns:DataObject>
    </ns:PageMap>
    <image:image>
      <image:loc>https://mms.businesswire.com/media/20260109704999/ja/2687178/21/Biocytogen-Acepodia-HI-EN.jpg</image:loc>
    </image:image>
  </url>
  <url>
    <loc>https://www.businesswire.com/news/home/20260109931541/zh-HK</loc>
    <lastmod>2026-01-10T02:51:00.000Z</lastmod>
    <changefreq>weekly</changefreq>
    <priority>0.5</priority>
    <news:news>
      <news:publication>
        <news:name>Business Wire</news:name>
        <news:language>zh-HK</news:language>
      </news:publication>
      <news:genres>PressRelease</news:genres>
      <news:publication_date>2026-01-10T02:51:00.000Z</news:publication_date>
      <news:title>百奧賽圖宣布與育世博達成進一步合作，共同推進同類首創雙特異性抗體雙藥物偶聯物（BsAD2C）專案</news:title>
      <news:stock_tickers>688796,02315</news:stock_tickers>
    </news:news>
    <ns:PageMap>
      <ns:DataObject type="thumbnail">
        <ns:Attribute name="name" value=""/>
        <ns:Attribute name="src" value="https://mms.businesswire.com/media/20260109931541/zh-HK/2687179/21/Biocytogen-Acepodia-HI-CN.jpg"/>
        <ns:Attribute name="width" value="150"/>
        <ns:Attribute name="height" value="150"/>
      </ns:DataObject>
    </ns:PageMap>
    <image:image>
      <image:loc>https://mms.businesswire.com/media/20260109931541/zh-HK/2687179/21/Biocytogen-Acepodia-HI-CN.jpg</image:loc>
    </image:image>
  </url>
  <url>
    <loc>https://www.businesswire.com/news/home/20260109764884/es</loc>
    <lastmod>2026-01-10T02:28:00.000Z</lastmod>
    <changefreq>weekly</changefreq>
    <priority>0.5</priority>
    <news:news>
      <news:publication>
        <news:name>Business Wire</news:name>
        <news:language>es</news:language>
      </news:publication>
      <news:genres>PressRelease</news:genres>
      <news:publication_date>2026-01-10T02:28:00.000Z</news:publication_date>
      <news:title>La NASA busca científicos noveles y expertos para las becas de prestigio del programa posdoctoral en sus centros de todo Estados Unidos</news:title>
    </news:news>
    <ns:PageMap>
      <ns:DataObject type="thumbnail">
        <ns:Attribute name="name" value=""/>
        <ns:Attribute name="src" value="https://mms.businesswire.com/media/20260109764884/es/401579/21/ORAU_Logo.jpg"/>
        <ns:Attribute name="width" value="150"/>
        <ns:Attribute name="height" value="150"/>
      </ns:DataObject>
    </ns:PageMap>
    <image:image>
      <image:loc>https://mms.businesswire.com/media/20260109764884/es/401579/21/ORAU_Logo.jpg</image:loc>
    </image:image>
  </url>
  <url>
    <loc>https://www.businesswire.com/news/home/20260109782710/en/Ardent-Health-Corporation-Securities-Fraud-Class-Action-Result-of-Undisclosed-Financial-Problems-and-33-Stock-Decline---Investors-may-Contact-Lewis-Kahn-Esq-at-Kahn-Swick-Foti-LLC</loc>
    <lastmod>2026-01-10T02:14:00.000Z</lastmod>
    <changefreq>weekly</changefreq>
    <priority>0.5</priority>
    <news:news>
      <news:publication>
        <news:name>Business Wire</news:name>
        <news:language>en</news:language>
      </news:publication>
      <news:genres>PressRelease</news:genres>
      <news:publication_date>2026-01-10T02:14:00.000Z</news:publication_date>
      <news:title>Ardent Health Corporation Securities Fraud Class Action Result of Undisclosed Financial Problems and 33% Stock Decline - Investors may Contact Lewis Kahn, Esq, at Kahn Swick &amp; Foti, LLC</news:title>
      <news:stock_tickers>ARDT</news:stock_tickers>
    </news:news>
    <ns:PageMap>
      <ns:DataObject type="thumbnail">
        <ns:Attribute name="name" value=""/>
        <ns:Attribute name="src" value="https://mms.businesswire.com/media/20260109782710/en/2664611/21/2025-PR-SEC.jpg"/>
        <ns:Attribute name="width" value="150"/>
        <ns:Attribute name="height" value="150"/>
      </ns:DataObject>
    </ns:PageMap>
    <image:image>
      <image:loc>https://mms.businesswire.com/media/20260109782710/en/2664611/21/2025-PR-SEC.jpg</image:loc>
    </image:image>
  </url>
  <url>
    <loc>https://www.businesswire.com/news/home/20260109884241/en/Summit-Therapeutics-Reports-Inducement-Grants-Under-Nasdaq-Listing-Rule-5635c4</loc>
    <lastmod>2026-01-10T01:16:00.000Z</lastmod>
    <changefreq>weekly</changefreq>
    <priority>0.5</priority>
    <news:news>
      <news:publication>
        <news:name>Business Wire</news:name>
        <news:language>en</news:language>
      </news:publication>
      <news:genres>PressRelease</news:genres>
      <news:publication_date>2026-01-10T01:16:00.000Z</news:publication_date>
      <news:title>Summit Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)</news:title>
      <news:stock_tickers>SMMT</news:stock_tickers>
    </news:news>
    <ns:PageMap>
      <ns:DataObject type="thumbnail">
        <ns:Attribute name="name" value=""/>
        <ns:Attribute name="src" value="https://mms.businesswire.com/media/20260109884241/en/2208782/21/2024-Summit-logo-RGB.jpg"/>
        <ns:Attribute name="width" value="150"/>
        <ns:Attribute name="height" value="150"/>
      </ns:DataObject>
    </ns:PageMap>
    <image:image>
      <image:loc>https://mms.businesswire.com/media/20260109884241/en/2208782/21/2024-Summit-logo-RGB.jpg</image:loc>
    </image:image>
  </url>
  <url>
    <loc>https://www.businesswire.com/news/home/20260109075473/en/Metropolitan-Issues-Statement-on-Federal-Release-of-Draft-EIS-for-Colorado-River-Operations</loc>
    <lastmod>2026-01-10T01:02:00.000Z</lastmod>
    <changefreq>weekly</changefreq>
    <priority>0.5</priority>
    <news:news>
      <news:publication>
        <news:name>Business Wire</news:name>
        <news:language>en</news:language>
      </news:publication>
      <news:genres>PressRelease</news:genres>
      <news:publication_date>2026-01-10T01:02:00.000Z</news:publication_date>
      <news:title>Metropolitan Issues Statement on Federal Release of Draft EIS for Colorado River Operations</news:title>
    </news:news>
    <ns:PageMap>
      <ns:DataObject type="thumbnail">
        <ns:Attribute name="name" value=""/>
        <ns:Attribute name="src" value="https://mms.businesswire.com/media/20260109075473/en/1110664/21/MWD_Seal_1_inch.jpg"/>
        <ns:Attribute name="width" value="150"/>
        <ns:Attribute name="height" value="150"/>
      </ns:DataObject>
    </ns:PageMap>
    <image:image>
      <image:loc>https://mms.businesswire.com/media/20260109075473/en/1110664/21/MWD_Seal_1_inch.jpg</image:loc>
    </image:image>
  </url>
  <url>
    <loc>https://www.businesswire.com/news/home/20260109786549/en/MindWalk-Advances-Universal-Influenza-Program-with-a-Breakthrough-Functional-Insight</loc>
    <lastmod>2026-01-10T01:01:00.000Z</lastmod>
    <changefreq>weekly</changefreq>
    <priority>0.5</priority>
    <news:news>
      <news:publication>
        <news:name>Business Wire</news:name>
        <news:language>en</news:language>
      </news:publication>
      <news:genres>PressRelease</news:genres>
      <news:publication_date>2026-01-10T01:01:00.000Z</news:publication_date>
      <news:title>MindWalk Advances Universal Influenza Program with a Breakthrough Functional Insight</news:title>
      <news:stock_tickers>HYFT</news:stock_tickers>
    </news:news>
    <ns:PageMap>
      <ns:DataObject type="thumbnail">
        <ns:Attribute name="name" value=""/>
        <ns:Attribute name="src" value="https://mms.businesswire.com/media/20260109786549/en/2586413/21/Mindwalk_fullcolor_RGB_LG.jpg"/>
        <ns:Attribute name="width" value="150"/>
        <ns:Attribute name="height" value="150"/>
      </ns:DataObject>
    </ns:PageMap>
    <image:image>
      <image:loc>https://mms.businesswire.com/media/20260109786549/en/2586413/21/Mindwalk_fullcolor_RGB_LG.jpg</image:loc>
    </image:image>
  </url>
  <url>
    <loc>https://www.businesswire.com/news/home/20260109206904/en/VRNS-Investors-Have-Opportunity-to-Lead-Varonis-Systems-Inc.-Securities-Fraud-Lawsuit-with-the-Schall-Law-Firm</loc>
    <lastmod>2026-01-10T01:00:00.000Z</lastmod>
    <changefreq>weekly</changefreq>
    <priority>0.5</priority>
    <news:news>
      <news:publication>
        <news:name>Business Wire</news:name>
        <news:language>en</news:language>
      </news:publication>
      <news:genres>PressRelease</news:genres>
      <news:publication_date>2026-01-10T01:00:00.000Z</news:publication_date>
      <news:title>VRNS Investors Have Opportunity to Lead Varonis Systems, Inc. Securities Fraud Lawsuit with the Schall Law Firm</news:title>
      <news:stock_tickers>VRNS</news:stock_tickers>
    </news:news>
    <ns:PageMap>
      <ns:DataObject type="thumbnail">
        <ns:Attribute name="name" value=""/>
        <ns:Attribute name="src" value="https://mms.businesswire.com/media/20260109206904/en/827144/21/Schall-Firm-Logo-640x360.jpg"/>
        <ns:Attribute name="width" value="150"/>
        <ns:Attribute name="height" value="150"/>
      </ns:DataObject>
    </ns:PageMap>
    <image:image>
      <image:loc>https://mms.businesswire.com/media/20260109206904/en/827144/21/Schall-Firm-Logo-640x360.jpg</image:loc>
    </image:image>
  </url>
  <url>
    <loc>https://www.businesswire.com/news/home/20260109843838/en/FCX-INVESTORS-Contact-Kirby-McInerney-LLP-About-Securities-Class-Action-Lawsuit-On-Behalf-of-Freeport-McMoran-Inc.</loc>
    <lastmod>2026-01-10T01:00:00.000Z</lastmod>
    <changefreq>weekly</changefreq>
    <priority>0.5</priority>
    <news:news>
      <news:publication>
        <news:name>Business Wire</news:name>
        <news:language>en</news:language>
      </news:publication>
      <news:genres>PressRelease</news:genres>
      <news:publication_date>2026-01-10T01:00:00.000Z</news:publication_date>
      <news:title>FCX INVESTORS: Contact Kirby McInerney LLP About Securities Class Action Lawsuit On Behalf of Freeport-McMoran Inc.</news:title>
      <news:stock_tickers>FCX</news:stock_tickers>
    </news:news>
    <ns:PageMap>
      <ns:DataObject type="thumbnail">
        <ns:Attribute name="name" value=""/>
        <ns:Attribute name="src" value="https://mms.businesswire.com/media/20260109843838/en/774509/21/new_KM_logo.jpg"/>
        <ns:Attribute name="width" value="150"/>
        <ns:Attribute name="height" value="150"/>
      </ns:DataObject>
    </ns:PageMap>
    <image:image>
      <image:loc>https://mms.businesswire.com/media/20260109843838/en/774509/21/new_KM_logo.jpg</image:loc>
    </image:image>
  </url>
  <url>
    <loc>https://www.businesswire.com/news/home/20260109047116/en/KBRA-Releases-Monthly-CMBS-Trend-Watch</loc>
    <lastmod>2026-01-10T00:55:00.000Z</lastmod>
    <changefreq>weekly</changefreq>
    <priority>0.5</priority>
    <news:news>
      <news:publication>
        <news:name>Business Wire</news:name>
        <news:language>en</news:language>
      </news:publication>
      <news:genres>PressRelease</news:genres>
      <news:publication_date>2026-01-10T00:55:00.000Z</news:publication_date>
      <news:title>KBRA Releases Monthly CMBS Trend Watch</news:title>
    </news:news>
    <ns:PageMap>
      <ns:DataObject type="thumbnail">
        <ns:Attribute name="name" value=""/>
        <ns:Attribute name="src" value="https://mms.businesswire.com/media/20260109047116/en/2688003/21/kbra-logo.jpg"/>
        <ns:Attribute name="width" value="150"/>
        <ns:Attribute name="height" value="150"/>
      </ns:DataObject>
    </ns:PageMap>
    <image:image>
      <image:loc>https://mms.businesswire.com/media/20260109047116/en/2688003/21/kbra-logo.jpg</image:loc>
    </image:image>
  </url>
  <url>
    <loc>https://www.businesswire.com/news/home/20260108972272/en/Peak-Technology-Unveils-APEX-A-Product-Development-Realization-Platform-Designed-to-Provide-Deep-Tech-OEMs-with-Rapid-Prototyping-New-Product-Introduction-and-High-Volume-Manufacturing-Solutions</loc>
    <lastmod>2026-01-10T00:50:00.000Z</lastmod>
    <changefreq>weekly</changefreq>
    <priority>0.5</priority>
    <news:news>
      <news:publication>
        <news:name>Business Wire</news:name>
        <news:language>en</news:language>
      </news:publication>
      <news:genres>PressRelease</news:genres>
      <news:publication_date>2026-01-10T00:50:00.000Z</news:publication_date>
      <news:title>Peak Technology Unveils APEX: A Product Development &amp; Realization Platform Designed to Provide Deep Tech OEMs with Rapid Prototyping, New Product Introduction, and High Volume Manufacturing Solutions</news:title>
    </news:news>
    <ns:PageMap>
      <ns:DataObject type="thumbnail">
        <ns:Attribute name="name" value=""/>
        <ns:Attribute name="src" value="https://mms.businesswire.com/media/20260108972272/en/2317644/21/Peak_Full_Logo.jpg"/>
        <ns:Attribute name="width" value="150"/>
        <ns:Attribute name="height" value="150"/>
      </ns:DataObject>
    </ns:PageMap>
    <image:image>
      <image:loc>https://mms.businesswire.com/media/20260108972272/en/2317644/21/Peak_Full_Logo.jpg</image:loc>
    </image:image>
  </url>
  <url>
    <loc>https://www.businesswire.com/news/home/20260109082615/en/Strong-Tower-Consulting-Named-Best-Places-to-Work-Redefining-Consulting-Delivery-with-Enterprise-Grade-AI</loc>
    <lastmod>2026-01-10T00:06:00.000Z</lastmod>
    <changefreq>weekly</changefreq>
    <priority>0.5</priority>
    <news:news>
      <news:publication>
        <news:name>Business Wire</news:name>
        <news:language>en</news:language>
      </news:publication>
      <news:genres>PressRelease</news:genres>
      <news:publication_date>2026-01-10T00:06:00.000Z</news:publication_date>
      <news:title>Strong Tower Consulting Named “Best Places to Work,” Redefining Consulting Delivery with Enterprise-Grade AI</news:title>
    </news:news>
    <ns:PageMap>
      <ns:DataObject type="thumbnail">
        <ns:Attribute name="name" value=""/>
        <ns:Attribute name="src" value="https://mms.businesswire.com/media/20260109082615/en/812315/21/Strong_Tower_logo_color.jpg"/>
        <ns:Attribute name="width" value="150"/>
        <ns:Attribute name="height" value="150"/>
      </ns:DataObject>
    </ns:PageMap>
    <image:image>
      <image:loc>https://mms.businesswire.com/media/20260109082615/en/812315/21/Strong_Tower_logo_color.jpg</image:loc>
    </image:image>
  </url>
</urlset>